Thus, treating prostate cancer cells in a hypoxic TME with the SLC25A1 inhibitor, 1,2,3-benzene-tricarboxylic acid (BTA) could not only yield direct tumor-specific killing, but it could also potentiate the activity of concomitant radiation or chemotherapy interventions. This evidence concerns the gene SLC25A1 and neoplasm.